PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1645262-5	1991	Treatment of immature hypophysectomized diethylstilbestrol-primed rats with a GnRH agonist (25 micrograms/rat, twice daily) for 2.5 days resulted in a 2.1-fold decrease in FSH (10 micrograms/rat, twice daily)-inducible (but not basal) specific [125I]IGF-I binding to isolated granulosa cells.	Diethylstilbestrol	40-58	insulin-like growth factor 1	Rattus norvegicus	250-255	
2174350-6	1990	In vivo treatment of immature hypophysectomized rats with diethylstilbestrol reduced ovarian IGF-II mRNA levels while increasing IGF-I mRNA levels.	Diethylstilbestrol	58-76	insulin-like growth factor 1	Rattus norvegicus	93-98	
2721441-3	1989	The proportion of ovarian IGF-I to tubulin messenger RNA (mRNA) was increased to 176% of control values by treatment with diethylstilbestrol, while the ratio in liver was decreased to 64.4%.	Diethylstilbestrol	122-140	insulin-like growth factor 1	Rattus norvegicus	26-31	
2737167-8	1989	Treatment of immature (21-23 days old) hypophysectomized rats with a diethylstilbestrol (DES)-containing subcutaneous silastic implant for a total of 5 days resulted in a 2-fold increase in the (densitometrically quantified) abundance of ovarian IGF-I transcripts, a diametrically-opposed effect (2.6-fold decrease) being noted at the level of the liver.	Diethylstilbestrol	69-87	insulin-like growth factor 1	Rattus norvegicus	246-251	
2737167-8	1989	Treatment of immature (21-23 days old) hypophysectomized rats with a diethylstilbestrol (DES)-containing subcutaneous silastic implant for a total of 5 days resulted in a 2-fold increase in the (densitometrically quantified) abundance of ovarian IGF-I transcripts, a diametrically-opposed effect (2.6-fold decrease) being noted at the level of the liver.	Diethylstilbestrol	89-92	insulin-like growth factor 1	Rattus norvegicus	246-251	
2737167-10	1989	In contrast, combined treatment with oGH and DES yielded a 3-fold increase in the abundance of ovarian IGF-I transcripts, there being no net alteration in hepatic IGF-I gene expression.	Diethylstilbestrol	45-48	insulin-like growth factor 1	Rattus norvegicus	103-108	
2964363-2	1988	In vivo treatment of immature hypophysectomized diethylstilbestrol-treated rats with increasing doses (0.3-30 microgram/rat, twice daily) of FSH for 72 h resulted in dose-dependent increments in specific granulosa cell somatomedin-C (Sm-C)/IGF-I binding, peaking (5150 +/- 350 cpm/3 x 10(5) cells) at the 10 micrograms/rat (twice daily) dose level to yield a 2.6-fold increase relative to that in untreated controls.	Diethylstilbestrol	48-66	insulin-like growth factor 1	Rattus norvegicus	240-245	
18427555-4	2008	To identify early events involved in the development of hyperplasia in the endometrium, we examined expression and activation of IGF-I pathway components in endometrium of rats exposed to DES.	Diethylstilbestrol	188-191	insulin-like growth factor 1	Rattus norvegicus	129-134	
1928375-7	1991	Body weight gain, food utilization, and nitrogen balance during the treatment period were significantly increased in rats treated with IGF-I at both the lower and higher doses and in those treated with des-(1-3)IGF-I.	Diethylstilbestrol	202-205	insulin-like growth factor 1	Rattus norvegicus	211-216	
1928375-8	1991	The improved nitrogen balance in the des-(1-3)IGF-I group could at least partly be explained by a diminished rate of muscle protein breakdown, as indicated by the reduced urinary excretion rate of 3-methylhistidine.	Diethylstilbestrol	37-40	insulin-like growth factor 1	Rattus norvegicus	46-51